Persons with rheumatoid arthritis (RA) commonly use glucocorticoids to manage their disease. Study authors seek to determine how providers prescribe glucocorticoids to commercially insured, newly diagnosed patients with RA in the United States.
Researchers evaluated grey scale ultrasound and power Doppler ultrasound synovitis to predict joint damage progression in rheumatoid arthritis.
Researchers reported on the efficacy and safety of 300 mg or 150 mg secukinumab in managing axial manifestations in patients with psoriatic arthritis.
This study was conducted to assess the long-term clinical efficacy of etanercept in patients with early axial spondyloarthritis, who participated in the ESTHER trial.
Findings showed somewhat higher rates of treated depression among patients with psoriatic arthritis exposed to corticosteroids alone or in combination with any other study drug and among patients exposed to interleukin inhibitors alone or in combination with DMARDs.
Tumor necrosis factor inhibitors slow radiologic progression when compared to other drug classes in ankylosing spondylitis.
Researchers compared the association of potential risk factors for the development of psoriasis, psoriatic arthritis, rheumatoid arthritis, and ankylosing spondylitis.
Researchers performed a systematic review of clinical practice guidelines to identify nonpharmacologic recommendations for osteoporosis treatment.
Researchers evaluated the efficacy and safety of guselkumab in patients with active psoriatic arthritis who were biologic-naive or treated with prior tumor necrosis factor inhibitors.
The study authors examined the association between rheumatoid arthritis disease activity and different dimensions of sleep quality.
